Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
暂无分享,去创建一个
R. Eckel | P. Rothenberg | I. Goldberg | A. Mullick | J. Obunike | Debapriya Basu | L. Huggins | N. D. Di Prospero | Diego Scerbo | Joseph C. Obunike
[1] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[2] R. Eckel,et al. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins , 2017, Hormone and Metabolic Research.
[3] K. Park,et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet , 2017, Diabetologia.
[4] R. Tian,et al. Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. , 2016, Journal of molecular and cellular cardiology.
[5] Nidhi Agrawal,et al. Triglyceride Treatment in the Age of Cholesterol Reduction. , 2016, Progress in cardiovascular diseases.
[6] Kunihiro Suzuki,et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes , 2016, Diabetology & Metabolic Syndrome.
[7] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[8] R. DeFronzo,et al. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study , 2016, Diabetes Care.
[9] T. Sulpice,et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism , 2016, Diabetes.
[10] Dermot F. Reilly,et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .
[11] Alexander E. Lopez,et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.
[12] Shaodong Guo,et al. Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function. , 2016, Circulation research.
[13] A. Nakajima,et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice , 2016, PloS one.
[14] T. Hirano,et al. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice , 2015, PloS one.
[15] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[16] E. Fisher,et al. Lipolysis, and Not Hepatic Lipogenesis, Is the Primary Modulator of Triglyceride Levels in Streptozotocin-Induced Diabetic Mice , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[17] T. Kuo,et al. Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin , 2014, Journal of Lipid Research.
[18] R. DeFronzo,et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.
[19] R. Rodríguez‐Gutiérrez,et al. Canagliflozin (November 2013) , 2014, Cleveland Clinic Journal of Medicine.
[20] R. Tian,et al. Rescue of heart lipoprotein lipase-knockout mice confirms a role for triglyceride in optimal heart metabolism and function. , 2013, American journal of physiology. Endocrinology and metabolism.
[21] H. Weintraub,et al. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. , 2013, Atherosclerosis.
[22] S. Mudaliar,et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion , 2013, Diabetes Care.
[23] A. Tall,et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. , 2013, Cell metabolism.
[24] É. Hardy,et al. Effects of Dapagliflozin on Cardiovascular Risk Factors , 2013, Postgraduate medicine.
[25] R. Eckel,et al. Angiopoietin-Like 4 Mediates PPAR Delta Effect on Lipoprotein Lipase-Dependent Fatty Acid Uptake but Not on Beta-Oxidation in Myotubes , 2012, PloS one.
[26] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[27] S. Kersten,et al. Induction of Cardiac Angptl4 by Dietary Fatty Acids Is Mediated by Peroxisome Proliferator-Activated Receptor &bgr;/&dgr; and Protects Against Fatty Acid–Induced Oxidative Stress , 2010, Circulation research.
[28] F. Schick,et al. Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator–Activated Receptor (PPAR)-δ and Is of Metabolic Relevance in Humans , 2009, Diabetes.
[29] R. DeFronzo,et al. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[30] B. Nordestgaard,et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.
[31] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[32] Stefan Neubauer,et al. The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.
[33] T. Olivecrona,et al. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue , 2006, Proceedings of the National Academy of Sciences.
[34] Chari D Smith,et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. , 2005, Diabetes.
[35] D. Rader,et al. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339 Published, JLR Papers in Press, July 1, 2005. DOI 10.1194/jlr.D500019-JLR200 , 2005, Journal of Lipid Research.
[36] Kenny K. Wong,et al. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Chait,et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. , 2004, The Journal of clinical investigation.
[38] W. Wahli,et al. The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment* , 2004, Journal of Biological Chemistry.
[39] George Steiner,et al. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. , 2002, Diabetes care.
[40] P. Chambon,et al. Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene* , 2000, The Journal of Biological Chemistry.
[41] J. Hocquette,et al. Lipoprotein lipase activity and mRNA levels in bovine tissues. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.
[42] W. Harris,et al. n-3 fatty acids and serum lipoproteins: animal studies. , 1997, The American journal of clinical nutrition.
[43] R. DeFronzo,et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.
[44] R. Eckel,et al. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. , 1982, The Journal of clinical investigation.
[45] J. Folch,et al. A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.
[46] D. Earle,et al. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. , 1951, The Journal of clinical investigation.
[47] Alexander E. Lopez,et al. Inactivating Variants in ANGPTL 4 and Risk of Coronary Artery Disease , 2016 .
[48] Shaodong Guo,et al. Cardiac Myocyte KLF 5 Regulates Ppara Expression and Cardiac Function , 2015 .
[49] S. Kersten,et al. Induction of Cardiac Angptl 4 by Dietary Fatty Acids Is Mediated by Peroxisome Proliferator-Activated Receptor / and Protects Against Fatty Acid – Induced Oxidative Stress , 2010 .
[50] C. Folmes,et al. Myocardial fatty acid metabolism in health and disease. , 2010, Physiological reviews.
[51] N. Lewis,et al. Phlorizin: a review , 2005, Diabetes/metabolism research and reviews.
[52] W. Harris,et al. n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.